0,83$ Dividende bei einen Aktienpreis von 1,22!!!!!!!!! 70% Dividende!!!!!! - 500 Beiträge pro Seite
eröffnet am 01.05.01 14:23:05 von
neuester Beitrag 01.05.01 14:54:51 von
neuester Beitrag 01.05.01 14:54:51 von
Beiträge: 6
ID: 393.278
ID: 393.278
Aufrufe heute: 0
Gesamt: 468
Gesamt: 468
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
02.05.24, 18:44 | 405 | |
24.05.13, 08:11 | 140 | |
vor 19 Minuten | 137 | |
gestern 13:40 | 93 | |
gestern 20:01 | 85 | |
24.01.14, 16:47 | 69 | |
gestern 22:24 | 67 | |
gestern 18:18 | 65 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.440,00 | +1,28 | 298 | |||
2. | 2. | 165,15 | -3,56 | 141 | |||
3. | 4. | 4,4000 | +12,82 | 101 | |||
4. | 3. | 10,660 | +0,76 | 93 | |||
5. | 6. | 0,1960 | 0,00 | 64 | |||
6. | 5. | 6,8400 | -1,16 | 64 | |||
7. | 7. | 11,578 | -7,14 | 56 | |||
8. | 8. | 6,7190 | -1,16 | 54 |
Die Firma heißt: OPHIDIAN PHARM (OPHD) OTCBB Aktie
hier steht es: http://www.nasdaqtrader.com/asp/dl_sec46.asp?ddate=04/30/200…
good luck and as always: do your own dd
morchel
http://www.zockstocks.com.....Aktien für den hochspekulativen Anleger
hier steht es: http://www.nasdaqtrader.com/asp/dl_sec46.asp?ddate=04/30/200…
good luck and as always: do your own dd
morchel
http://www.zockstocks.com.....Aktien für den hochspekulativen Anleger
dann bleibt ja nach dem dividendenabzug fast nichts mehr vom kurs übrig...
Ophidian Pharmaceuticals, Inc. (OTC Bulletin Board: OPHD.OB - news; ``Ophidian`` or ``the Company``) announced today that it will make a distribution to its existing stockholders of record as of April 23, 2001. The distribution will be in the amount of Eighty-three cents ($0.83) per share, and payment is scheduled to be mailed to stockholders on or about April 30, 2001. This distribution represents most of the proceeds the Company received from the sale of its assets to Promega Corporation on November 16, 2000. The Company has retained the remaining portion of the proceeds to cover certain operating expenses, taxes, other costs, and remaining liabilities of the Company, including any liabilities that arise after the closing of its Agreement and Plan of Merger with Hemoxymed, Inc. (``Hemoxymed``), as previously announced. After payment of its remaining liabilities, a final distribution of any remaining proceeds, if any, from the sale of its assets to Promega Corporation will be made following the closing of the Company`s Agreement and Plan of Merger with Hemoxymed.
The Company also announced that as of April 16, 2001, Ophidian and Hemoxymed entered into an Agreement and Plan of Merger whereby Ophidian will acquire all of Hemoxymed`s outstanding capital stock from Hemoxymed shareholders in exchange for Ophidian`s issuance and delivery to Hemoxymed shareholders of 19,000,000 new, unregistered shares of the Company`s common stock. Immediately following the closing of the transaction, the Company will have 20,200,000 shares of its common stock issued and outstanding, of which Hemoxymed shareholders will hold approximately 94% and the Ophidian stockholders immediately prior to the transaction will hold the remaining 6%, and Hemoxymed will become a wholly owned subsidiary of the Company.
As previously announced, the parties expect to rename the Company ``HEMOXymed, Inc.`` and its subsidiary will continue Hemoxymed`s current business, which is the development of a process designed to increase tissue oxygenation for the treatment of a wide range of diseases. The transaction is expected to be tax-free to the stockholders of both companies. The closing of the transaction is subject to customary conditions, including the approval of the stockholders of both Ophidian and Hemoxymed.
NOTE: ``Safe Harbor`` Statement under the Private Securities Litigation Reform Act of 1995: This document contains certain forward-looking statements based on the Company`s expectations. There are certain key factors that could cause future results to differ from those anticipated by the Company`s management and Board of Directors, including but not limited to the risk that the Company may not be able to complete the merger with, as well as any unanticipated claims and liabilities that might arise during the process of liquidating and winding up the Company`s business and affairs.
Des Rätsels Lösung.
Gruß
Sigi
The Company also announced that as of April 16, 2001, Ophidian and Hemoxymed entered into an Agreement and Plan of Merger whereby Ophidian will acquire all of Hemoxymed`s outstanding capital stock from Hemoxymed shareholders in exchange for Ophidian`s issuance and delivery to Hemoxymed shareholders of 19,000,000 new, unregistered shares of the Company`s common stock. Immediately following the closing of the transaction, the Company will have 20,200,000 shares of its common stock issued and outstanding, of which Hemoxymed shareholders will hold approximately 94% and the Ophidian stockholders immediately prior to the transaction will hold the remaining 6%, and Hemoxymed will become a wholly owned subsidiary of the Company.
As previously announced, the parties expect to rename the Company ``HEMOXymed, Inc.`` and its subsidiary will continue Hemoxymed`s current business, which is the development of a process designed to increase tissue oxygenation for the treatment of a wide range of diseases. The transaction is expected to be tax-free to the stockholders of both companies. The closing of the transaction is subject to customary conditions, including the approval of the stockholders of both Ophidian and Hemoxymed.
NOTE: ``Safe Harbor`` Statement under the Private Securities Litigation Reform Act of 1995: This document contains certain forward-looking statements based on the Company`s expectations. There are certain key factors that could cause future results to differ from those anticipated by the Company`s management and Board of Directors, including but not limited to the risk that the Company may not be able to complete the merger with, as well as any unanticipated claims and liabilities that might arise during the process of liquidating and winding up the Company`s business and affairs.
Des Rätsels Lösung.
Gruß
Sigi
Ophidian Pharmaceuticals, Inc. Announces a Distribution to Stockholders And The Signing of
an Agreement and Plan of Merger With Hemoxymed, Inc.
http://biz.yahoo.com/prnews/010416/mnm035.html
MADISON, Wis., April 16 /PRNewswire/ --
Ophidian Pharmaceuticals, Inc. (OTC Bulletin Board: OPHD.OB - news; ``Ophidian`` or ``the Company``) announced today that it will make a distribution to its
existing stockholders of record as of April 23, 2001. The distribution will be in the amount of Eighty-three cents ($0.83) per share, and payment is scheduled to be
mailed to stockholders on or about April 30, 2001.
Hier heißt es record date 23.04. Heute ist aber bereits der 1.05.
mfg Mars
an Agreement and Plan of Merger With Hemoxymed, Inc.
http://biz.yahoo.com/prnews/010416/mnm035.html
MADISON, Wis., April 16 /PRNewswire/ --
Ophidian Pharmaceuticals, Inc. (OTC Bulletin Board: OPHD.OB - news; ``Ophidian`` or ``the Company``) announced today that it will make a distribution to its
existing stockholders of record as of April 23, 2001. The distribution will be in the amount of Eighty-three cents ($0.83) per share, and payment is scheduled to be
mailed to stockholders on or about April 30, 2001.
Hier heißt es record date 23.04. Heute ist aber bereits der 1.05.
mfg Mars
Heute ist Ex-Div.
Div.Pay Date war 03.04.
Quelle Yahoo Finance
Div.Pay Date war 03.04.
Quelle Yahoo Finance
...schön wärs gewesen!
hab ich leider in der euphorie übersehen!
sorry
morchel
hab ich leider in der euphorie übersehen!
sorry
morchel
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
298 | ||
141 | ||
101 | ||
93 | ||
64 | ||
64 | ||
56 | ||
54 | ||
43 | ||
43 |
Wertpapier | Beiträge | |
---|---|---|
43 | ||
37 | ||
33 | ||
31 | ||
27 | ||
26 | ||
23 | ||
22 | ||
21 | ||
21 |